Theriva Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

Key Developments and Potential Share Price Catalysts

• FDA Alignment on Pivotal Phase 3 Trial for VCN-01 in Metastatic Pancreatic Cancer:

  Theriva Biologics has reached alignment with the FDA on the major elements of its proposed pivotal Phase 3 trial design for VCN-01 (zabilugene almadenorepvec), an oncolytic adenovirus for metastatic pancreatic ductal adenocarcinoma (PDAC). The trial will evaluate VCN-01 combined with standard-of-care chemotherapy (gemcitabine/nab-paclitaxel). The FDA feedback was consistent with prior advice from the EMA, notably supporting repeated dosing ‘macrocycles’ of VCN-01 and chemotherapy. This regulatory progress could significantly de-risk the clinical pathway and represents a major milestone, potentially influencing share value.

  Theriva plans to launch a dosing feasibility study at a single site in Spain in the second half of 2026, administering more frequent doses of VCN-01 over a longer period to generate feasibility data for the intended Phase 3 macrocycle regimen. This could further validate the trial approach and support regulatory submissions.

• Positive VIRAGE Phase 2b Data and Presentation at AACR:

  Additional analyses from the VIRAGE Phase 2b trial were presented at the AACR 2026 annual meeting. The data suggest a potential immune-mediated mechanism for VCN-01 in metastatic PDAC, with later and more durable responses and improved overall survival (OS) and progression-free survival (PFS) observed in VCN-01-treated patients across multiple subgroups—including patients with liver metastases. These results reinforce the promise of VCN-01 and could be a share price driver if the efficacy translates into Phase 3.

• Expansion into Retinoblastoma – Compassionate Use and Upcoming Clinical Trial:

  Theriva has made VCN-01 available for compassionate use in retinoblastoma, treating two patients with intravitreal VCN-01 in combination with topotecan. These cases will provide feasibility and tolerability data for a planned Phase 2/3 clinical trial targeting children with refractory retinoblastoma and vitreous seeds, a rare disease with high unmet need. If successful, this could open a new market and potentially drive future share value.

  The company aims to submit a clinical trial protocol to the FDA; if accepted, first patient enrollment is anticipated in December 2026, with rolling Biologic Licensing Application (BLA) submissions expected in 2029 and potential approval before September 30, 2029. This timeline provides shareholders a clear path to near-term milestones and long-term value creation.

• Financial Position and Cash Runway:

  Theriva reported cash and cash equivalents of \$14.4 million as of March 31, 2026, providing a cash runway into Q1 2027. The company’s cash position improved by \$1.4 million from December 31, 2025, primarily due to working capital management and operating activities. The net loss for Q1 2026 was \$2.0 million, down from \$23.7 million for the full year 2025. This improved cash position and reduced burn rate are positive for shareholders concerned about dilution and future financing needs.

• Operational Expense Trends:

  General and administrative expenses increased by 43% to \$2.1 million in Q1 2026 (vs. \$1.4 million in Q1 2025), driven by higher legal fees, investor relations, registration, and salary costs, as well as increased stock-based compensation. Conversely, research and development expenses fell sharply by 88% to \$355,000 due to the completion of the VIRAGE Phase 2b trial, recognition of the Spanish R&D rebate, and lower indirect costs. This reflects a transition period, with expenses expected to rise again once new trials commence.

• Pipeline Updates:

  – VCN-01 (Metastatic PDAC): Phase 3 trial in preparation; adaptive design to optimize timelines and outcomes.
  – VCN-01 (Retinoblastoma): Compassionate use ongoing, Phase 2/3 trial protocol in development.
  – SYN-004 (Ribaxamase): Two of three cohorts completed in allogeneic hematopoietic cell transplant (HCT) recipients; third cohort pending additional funding.
  – SYN-020: Higher patent expenses, limited preclinical studies ongoing.
  – VCN-X Discovery Program: Early-stage candidate (VCN-12) in preclinical evaluation.

• Risks and Forward-Looking Factors:

  The company’s ability to commence and fund pivotal trials, submit BLAs, achieve regulatory milestones, and commercialize products remains subject to risks including financing, competition, and clinical success. The initiation of the pivotal Phase 3 trial for VCN-01 is contingent on sufficient financing, and SYN-004 cohort 3 requires additional funds.

  The company also notes the risk of needing to raise capital or pursue strategic alternatives (business combination, merger, or reverse merger), which could affect share value and ownership structure.

Detailed Financials

• License Revenue: \$300,000 for Q1 2026 (none in Q1 2025)
• Net Loss: \$2.0 million for Q1 2026 (\$4.3 million Q1 2025)
• Shares Outstanding: 41,072,725 average in Q1 2026 (2,782,449 in Q1 2025)
• Comprehensive Loss: \$2.4 million for Q1 2026 (\$3.7 million Q1 2025)
• Balance Sheet: Total assets \$38.2 million; total liabilities \$22.8 million; stockholders’ equity \$15.4 million as of March 31, 2026.

Conclusion: Potential Share Price Movers

Theriva Biologics’ Q1 2026 report contains several potentially price-sensitive developments for investors:

• Regulatory alignment with FDA for a pivotal Phase 3 trial in metastatic PDAC
• Compelling Phase 2b efficacy data for VCN-01 (especially in difficult-to-treat liver metastases)
• Advancement into retinoblastoma, a rare pediatric cancer with high unmet need
• Improved cash position and operational expense management
• Clear timelines for clinical milestones and potential BLA submissions
• Risks related to financing and clinical trial initiation

These factors could influence investor sentiment and share price, especially as the company approaches clinical and regulatory catalysts.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties, including those described in Theriva Biologics’ SEC filings. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The author does not hold any position in Theriva Biologics at the time of writing.

View Theriva Biologics, Inc. Historical chart here